背俞穴为主埋线治疗脑卒中后假性球麻痹吞咽障碍

目的:观察背俞穴为主埋线治疗脑卒中后假性球麻痹吞咽障碍的临床疗效.方法:42例脑卒中后假性球麻痹致吞咽障碍患者,应用背俞穴为主行穴位埋线,10日埋1次,三次为一个疗程,采用吞咽功能评价量表评定疗效.结果:治愈25例,有效7例,无效10例,总有效率75.7%.结论:背俞穴为主埋线能对脑卒中后假性球麻痹吞咽障碍有改善作用.     

背俞穴治疗腹痛107例临床观察

腹痛是临床很多疾病常见的主要证状之一,按其的性质可分为急性与慢性二种。本人在临床中用背俞穴为主治疗各种原因引起的急慢性腹痛病人107例,效果满意,现介绍如下: 一般资料:107例病人中急性腹痛67例,慢性腹痛40例;男62例,女45例;年龄最小18岁,最大60岁;病程最短2年,最长达10年之久。 治疗方法;根据疼痛的部位所属脏器,取其相应的背俞穴,并配合表里脏腑、或配合临近脏器之背俞穴,如胆绞痛取肝、胆俞;胃脘部痛取脾、胃俞;腹痛取大肠     

局部取穴联合背俞穴埋线治疗中风后吞咽障碍的临床效果

目的 探讨局部取穴联合背俞穴埋线治疗中风后吞咽障碍的临床效果.方法 选取温州市中医院2019年4月-2020年4月收治的中风后吞咽障碍患者96例,根据随机数字表法随机分为观察组和对照组,每组48例.2组患者均给予规范化药物治疗.对照组患者在规范化药物治疗基础上行常规康复训练治疗,观察组在对照组常规康复训练基础上给予局部...     

背俞穴位置考

背俞穴位置考孙永平，甄薇（北京中医药大学针灸推拿系北京１０００２９）关键词经穴；背俞穴；定位背俞穴亦称脏腑背俞穴、俞穴，首载于《内经》。背俞穴是脏腑经气输注于背腰部的一些特定穴位，每一脏腑均有各自所属的背俞穴，共十二穴。背俞穴与其所属脏腑联系密切，古...     

针刺五脏背俞穴治疗失眠症的临床疗效

目的：观察针刺五脏背俞穴对失眠症有无效果。方法将60例失眠患者分为治疗组和对照组两个组。治疗组采用针刺五脏背俞穴,对照组采用传统的西医治疗。10天为一个疗程,治疗3个疗程后统计结果。结果对比治疗组和对照组,治疗组中睡眠质量提高者占80%,比对照组中的传统疗法有显著疗效（P＜0.05或者P＜0.01）。结论针刺五脏背俞穴的方法能够显著提高失眠患者的睡眠质量,睡眠时间和睡眠效率等方面。     

背俞穴药物注射治疗顽固性失眠28例疗效观察

目的：观察刺五加注射液治疗顽固性失眠的疗效。方法：利用刺五加注射液４ｍｌ背俞穴（心俞、脾俞、肝俞、肾俞）注射，每次选取一组穴位（双侧），交替使用。结果：观察２８例，治愈１７例，显效６例，有效３例，无效２例。治愈率为６１％，总有效率为９３％。结论：刺五加注射液背俞穴注射治疗顽固性失眠疗效显著。     

背俞穴拔罐放血治疗黄褐斑62例

黄褐斑多见于中青年女性，属中医“黧黑斑”范畴。本病面部皮肤有黄褐色斑块，形态大小不一，斑界清晰或模糊，邻近斑块有连片趋势。黄褐斑处皮肤光滑，无其它不适及自觉症状，主要分布于颧、颊、鼻、额、口唇四周，皮损日晒后可加重本病。由于本病有碍美观，很多患者为此苦恼不已。笔者采用刺血疗法治疗本病62例，收到了满意的疗效，现报告如下。     

针刺五脏背俞穴的临床体会

目的：评价针刺五脏背俞穴治疗相应脏腑疾病的临床应用。方法：选用临床有代表性的病例,通过辨证选用相对应的背俞穴进行针刺操作。结果：采用针刺背俞穴法的病例都达到了临床治愈的标准。结论：针刺背俞穴对于治疗相应五脏的病变具有较好的疗效,背俞穴相互配合应用,能够调整相应的脏腑阴阳的机理。     

谈脏腑背俞穴

<正> 脏腑背俞穴是脏腑经气输注于背腰部的腧穴.位于足太阳膀胱经的第一侧线上,大体依脏腑位置而上下排列,分别冠以脏腑之名,共12穴。本文仅对脏腑背俞源流、含义、定位、主治规律、配伍规律及针刺方法、注意事项作初步总结。一、背俞源流据古文学家研究,“尹”字,甲骨文为     

Acupoint Catgut Embedding Alleviates Insomnia in Different Chinese Medicine Syndrome Types: A Randomized Controlled Trial

Objective: To investigate the effects and safety of catgut embedding on alleviating insomnia. Methods: Totally 510 patients with insomnia were divided into 5 Chinese medicine (CM) syndrome types: Xin (Heart) and Pi (Spleen) deficiency, yin deficiency with excess fire, Xin and gut qi deficiency, Wei (Stomach) disorder, and qi and blood deficiency, respectively. These 5 types of patients were randomly assigned to a catgut embedding group, an acupuncture group or a medication group (30 cases in Xin and Pi deficiency type, Wei disorder type, Xin and gut qi deficiency type, respectively; 40 cases in yin deficiency with excess fire type and qi and blood deficiency type, respectively). In the catgut embedding group, patients were treated by implanting catgut into acupoints once every 10 days for a total of 30 days. In the acupuncture group, patients were treated with acupuncture once per day over 30 days (excluding weekends); and patients in the medication group took 1 mg Eurodin Tablet orally every night for 30 days. Pittsburgh Sleep Quality Index (PSQI) was evaluated before treatment, on 30 and 60 days after the first treatment, respectively. The International Unified Sleep Efficiency Value (IUSEV) was measured at 30 and 60 days. The safety was evaluated after treatment and adverse events were analyzed. Results: The objective PSQI scores including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, daytime dysfunction, and total scores at 30 days were significantly improved compared with pre-treatment in the catgut embedding and acupuncture groups (P<0.01 or P<0.05). At 30 days, the PSQI scores in catgut embedding group were superior to the medication group in the patients with each type of insomnia, with the exception of sleep duration (P<0.01 or P<0.05). At 60 days, significant differences were found between the catgut embedding group and the medication group (P<0.01 for all indices). The IUSEV scores in the catgut embedding group were significantly higher than the acupuncture group at 60 days, and the scores in acupuncture group were higher than the medication group at 30 days (P<0.05 for all types). No severe adverse events were found in this study. Conclusions: Acupoint catgut embedding and acupuncture were more effective than medication in alleviating insomnia syndrome in different Chinese medicine syndrome type. However, the sustained effects of acupoint catgut embedding were superior to acupuncture.     

耳穴贴压法治疗中风后抑郁随机对照研究

目的：评价耳穴贴压法治疗中风后抑郁（PSD）的疗效。方法：将114例符合试验要求的PSD病人按随机号随机进入试验组及对照组,各57例。试验组采用耳穴贴压法,对照组口服百忧解。两组均治疗8周,以汉密顿抑郁量表-21项（HAMD）、中国脑卒中临床神经功能缺损程度评分量表（神经功能缺损）和日常生活活动能力量表（BI）为观察指标,在治疗前、第2周末、第4周末、第8周末各检测1次,共4次。结果：试验组与对照组共有107例完成试验（分别为55例、52例）。试验组与对照组治疗后HAMD评分均有下降,试验组与对照组治疗后分值的下降均有统计学意义,但两组治疗后HAMD评分下降的差异无统计学意义。试验组与对照组治疗后神经功能缺损均有下降,试验组与对照组治疗后分值的下降均无统计学意义。同样,两组治疗后神经功能缺损下降的差异无统计学意义。两组治疗后BI评分均有提高,两组治疗后分值的提高均有统计学意义,同样,两组治疗后BI评分下降的差异无统计学意义。结论：耳穴贴压法治疗PSD可获得与百郁解相似的疗效。     

耳穴贴压法治疗中风后抑郁随机对照研究

目的:评价耳穴贴压法治疗中风后抑郁(PSD)的疗效。方法:将114例符合试验要求的PSD病人按随机号随机进入试验组及对照组,各57例。试验组采用耳穴贴压法,对照组口服百忧解。两组均治疗8周,以汉密顿抑郁量表-21项(HAMD)、中国脑卒中临床神经功能缺损程度评分量表(神经功能缺损)和日常生活活动能力量表(BI)为观察指标,在治疗前、第2周末、第4周末、第8周末各检测1次,共4次。结果:试验组与对照组共有107例完成试验(分别为55例、52例)。试验组与对照组治疗后HAMD评分均有下降,试验组与对照组治疗后分值的下降均有统计学意义,但两组治疗后HAMD评分下降的差异无统计学意义。试验组与对照组治疗后神经功能缺损均有下降,试验组与对照组治疗后分值的下降均无统计学意义。同样,两组治疗后神经功能缺损下降的差异无统计学意义。两组治疗后BI评分均有提高,两组治疗后分值的提高均有统计学意义,同样,两组治疗后BI评分下降的差异无统计学意义。结论:耳穴贴压法治疗PSD可获得与百郁解相似的疗效。     

Maintenance Phase Efficacy of Sertraline for Chronic Depression: A Randomized Controlled Trial

Context.— The chronic form of major depression is associated with a high rate of prevalence and disability, but no controlled research has examined the impact of long-term treatment on the course and burden of illness. Objective.— To determine if maintenance therapy with sertraline hydrochloride can effectively prevent recurrence of depression in the high-risk group of patients experiencing chronic major depression or major depression with antecedent dysthymic disorder ("double depression"). Design.— A 76-week randomized, double-blind, parallel-group study, conducted from September 1993 to November 1996. Setting.— Outpatient psychiatric clinics at 10 academic medical centers and 2 clinical research centers. Intervention.— Maintenance treatment with either sertraline hydrochloride (n=77) in flexible doses up to 200 mg or placebo (n=84). Patients.— A total of 161 outpatients with chronic major or double depression who responded to sertraline in a 12-week, double-blind, acute-phase treatment trial and continued to have a satisfactory therapeutic response during a subsequent 4-month continuation phase. Main Outcome Measure.— Time to recurrence of major depression. Results.— Sertraline afforded significantly greater prophylaxis against recurrence than did placebo (5 [6%] of 77 in the sertraline group vs 19 [23%] of 84 in the placebo group; P=.002 for the log-rank test of time-to-recurrence distributions). Clinically significant depressive symptoms reemerged in 20 (26%) of 77 patients treated with sertraline vs 42 (50%) of 84 patients who received placebo (P=.001). With use of a Cox proportional hazards model, patients receiving placebo were 4.07 times more likely (95% CI, 1.51-10.95; P=.005) to experience a depression recurrence, after adjustment for study site, type of depression, and randomization strata. Conclusions.— Maintenance therapy with sertraline is well tolerated and has significant efficacy in preventing recurrence or reemergence of depression in chronically depressed patients.      

穴位埋线联合穴位贴敷治疗咳嗽变异性哮喘的随机对照研究

目的:探讨穴位埋线联合穴位贴敷治疗咳嗽变异性哮喘患者的临床效果和安全性分析。方法:采用前瞻性分析法,选取咳嗽变异性哮喘患者120例。采用简单数字的随机方法随机分为治疗组和对照组,每组60例。治疗组给予常规治疗加穴位埋线联合穴位贴敷;对照组给予常规治疗加孟鲁司特咀嚼片口服。观察两组患者治疗前后细胞因子水平、症状积分变化及临床疗效,比较治疗后2组患者不良反应的发生率。结果:治疗后治疗组在细胞因子子(Hs-CRP、IL-8、TNF-α)水平、症候积分(咳嗽、咯痰、胸膈满闷)方面比较有显著性差异(P0.05);治疗组临床疗效总有效率为93.33%,对照组临床疗效总有效率为83.33%,2者比较差异有统计学意义(P0.05)。治疗组不良反应的发生率低于对照组(P0.05)。结论:穴位埋线联合穴位贴敷能够有效地缓解咳嗽变异性哮喘患者患者临床症状,安全性高,值得进一步推广及应用。     

Moxibustion for Correction of Breech Presentation: A Randomized Controlled Trial

Context.— Traditional Chinese medicine uses moxibustion (burning herbs to stimulate acupuncture points) of acupoint BL 67 (Zhiyin, located beside the outer corner of the fifth toenail), to promote version of fetuses in breech presentation. Its effect may be through increasing fetal activity. However, no randomized controlled trial has evaluated the efficacy of this therapy. Objective.— To evaluate the efficacy and safety of moxibustion on acupoint BL 67 to increase fetal activity and correct breech presentation. Design.— Randomized, controlled, open clinical trial. Setting.— Outpatient departments of the Women's Hospital of Jiangxi Province, Nanchang, and Jiujiang Women's and Children's Hospital in the People's Republic of China. Patients.— Primigravidas in the 33rd week of gestation with normal pregnancy and an ultrasound diagnosis of breech presentation. Interventions.— The 130 subjects randomized to the intervention group received stimulation of acupoint BL 67 by moxa (Japanese term for Artemisia vulgaris) rolls for 7 days, with treatment for an additional 7 days if the fetus persisted in the breech presentation. The 130 subjects randomized to the control group received routine care but no interventions for breech presentation. Subjects with persistent breech presentation after 2 weeks of treatment could undergo external cephalic version anytime between 35 weeks' gestation and delivery. Main Outcome Measures.— Fetal movements counted by the mother during 1 hour each day for 1 week; number of cephalic presentations during the 35th week and at delivery. Results.— The intervention group experienced a mean of 48.45 fetal movements vs 35.35 in the control group (P<.001; 95% confidence interval [CI] for difference, 10.56-15.60). During the 35th week of gestation, 98 (75.4%) of 130 fetuses in the intervention group were cephalic vs 62 (47.7%) of 130 fetuses in the control group (P<.001; relative risk [RR], 1.58; 95% CI, 1.29-1.94). Despite the fact that 24 subjects in the control group and 1 subject in the intervention group underwent external cephalic version, 98 (75.4%) of the 130 fetuses in the intervention group were cephalic at birth vs 81 (62.3%) of the 130 fetuses in the control group (P=.02; RR, 1.21; 95% CI, 1.02-1.43). Conclusion.— Among primigravidas with breech presentation during the 33rd week of gestation, moxibustion for 1 to 2 weeks increased fetal activity during the treatment period and cephalic presentation after the treatment period and at delivery.      

Effectiveness of Topic-specific Infobuttons: A Randomized Controlled Trial

Objective

Infobuttons are decision support tools that provide links within electronic medical record systems to relevant content in online information resources. The aim of infobuttons is to help clinicians promptly meet their information needs. The objective of this study was to determine whether infobutton links that direct to specific content topics (“topic links”) are more effective than links that point to general overview content (“nonspecific links”).

Design

Randomized controlled trial with a control and an intervention group. Clinicians in the control group had access to nonspecific links, while those in the intervention group had access to topic links.

Measurements

Infobutton session duration, number of infobutton sessions, session success rate, and the self-reported impact that the infobutton session produced on decision making.

Results

The analysis was performed on 90 subjects and 3,729 infobutton sessions. Subjects in the intervention group spent 17.4% less time seeking for information (35.5 seconds vs. 43 seconds, p = 0.008) than those in the control group. Subjects in the intervention group used infobuttons 20.5% (22 sessions vs. 17.5 sessions, p = 0.21) more often than in the control group, but the difference was not significant. The information seeking success rate was equally high in both groups (89.4% control vs. 87.2% intervention, p = 0.99). Subjects reported a high positive clinical impact (i.e., decision enhancement or knowledge update) in 62% of the sessions.

Limitations

The exclusion of users with a low frequency of infobutton use and the focus on medication-related information needs may limit the generalization of the results. The session outcomes measurement was based on clinicians'' self-assessment and therefore prone to bias.

Conclusion

The results support the hypothesis that topic links are more efficient than nonspecific links regarding the time seeking for information. It is unclear whether the statistical difference demonstrated will result in a clinically significant impact. However, the overall results confirm previous evidence that infobuttons are effective at helping clinicians to answer questions at the point of care and demonstrate a modest incremental change in the efficiency of information delivery for routine users of this tool.     

奥氮平与氟哌啶醇治疗谵妄的对照研究

目的比较非典型抗精神病药物奥氮平与传统抗精神病药物氟哌啶醇治疗谵妄的疗效和安全性。方法符合标准的98例谵妄病人随机分为奥氮平组（n=40）、氟哌啶醇组（n=38）和对照组（n=20）,用简明精神病评定量表（BPRS）、临床总体印象量表严重程度（CGI—SI）评定疗效,用副反应量表（TESS）和实验室检查评定不良反应和安全性。观察时间为期1周。结果奥氮平组、氟哌啶醇组和对照组的显效率分别为82．5％、78．9％o和30％,两治疗组和对照组比较,差异有显著性（P〈0．01）,两治疗组之间比较差异无显著性（P〉0．05）。奥氮平组不良反应总发生率为17．5％,氟哌啶醇组为52．6％,差异有显著性（P〈0.01）。结论奥氮平治疗谵妄病人安全有效,疗效与氟哌啶醇无差异,副反应较轻,可替代传统抗精神病药用于谵妄治疗。     

Abstract of Systematic Review of Randomized Controlled Trial of Traditional Chinese Medicine for the Treatment of Depression

In order to investigate the efficacious Chinese medicine for depression, 6 studies according with criteria and 367 randomized patients were included in this review. Compared with western medicine or western medicine plus other therapies or blank control, Chinese medicine can＇t lower the scores of self-rating depression scale （-1.58, 95%CI-3.39- -0.23, p=0.09）; but it is likely to lower the scores of Hamilton depression scale （-0.91, 95%CI-1.97-4）.15, p〈0.00001, 0 was included in the 95% CI）. Although the scores of Hamilton depression scale are possibly lowered, reviewer thinks that more proof is needed to authenticate the above-noted conclusion. The prospect of Chinese medicine for depression is promising; more qualified randomized controlled clinical trials are warranted to assure its efficacy.     

Chelation Therapy for Ischemic Heart Disease: A Randomized Controlled Trial

Context  Chelation therapy using EDTA is an unproven but widely used alternative therapy for ischemic heart disease. Objective  To determine if current EDTA protocols have a favorable impact on exercise ischemia threshold and quality of life measures in patients with stable ischemic heart disease. Design  Double-blind, randomized, placebo-controlled trial conducted between January 1996 and January 2000. Setting  Participants were recruited from a cohort of cardiac catheterization patients and the practices of cardiologists in Calgary, Alberta. Participants  We screened 3140 patients, performed a qualifying treadmill test in 171, and enrolled 84. Entry criteria included age at least 21 years with coronary artery disease proven by angiography or a documented myocardial infarction and stable angina while receiving optimal medical therapy. The required treadmill test used a gradual ramping protocol and patients had to demonstrate at least 1-mm ST depression. Interventions  Patients were randomly assigned to receive infusion with either weight-adjusted (40 mg/kg) EDTA chelation therapy (n = 41) or placebo (n = 43) for 3 hours per treatment, twice weekly for 15 weeks and once per month for an additional 3 months. Patients in both groups took oral multivitamin therapy as well. Main Outcome Measure  Change from baseline to 27-week follow-up in time to ischemia (1-mm ST depression). Results  Thirty-nine patients in each group completed the 27-week protocol. One chelation patient had therapy discontinued for a transient rise in serum creatinine. The mean (SD) baseline exercise time to ischemia was 572 (172) and 589 (176) seconds in the placebo and chelation groups, respectively. The corresponding mean changes in time to ischemia at 27 weeks were 54 seconds (95% confidence interval [CI], 23-84 seconds; P<.001) and 63 seconds (95% CI, 29-95 seconds; P<.001), for a difference of 9 seconds (95% CI, -36 to 53 seconds; P = .69). Exercise capacity and quality of life scores improved by similar degrees in both groups. Conclusion  Based on exercise time to ischemia, exercise capacity, and quality of life measurements, there is no evidence to support a beneficial effect of chelation therapy in patients with ischemic heart disease, stable angina, and a positive treadmill test for ischemia.